Pharmacoeconomics
Overview
PharmacoEconomics is a renowned peer-reviewed journal that focuses on the economic evaluation of pharmaceuticals and healthcare interventions. It provides a platform for researchers, policymakers, and industry professionals to explore cost-effectiveness, pricing, and reimbursement strategies. With a multidisciplinary approach, the journal offers valuable insights into the economic impact of healthcare decisions, aiding in informed decision-making and resource allocation.
Details
Details
Abbr.
Pharmacoeconomics
Start
1992
End
Continuing
Frequency
Twelve no. a year
p-ISSN
1170-7690
e-ISSN
1179-2027
Country
New Zealand
Language
English
Specialty
Pharmacology
Metrics
Metrics
h-index / Ranks: 2309
118
SJR / Ranks: 1927
1517
CiteScore / Ranks: 2355
7.80
JIF / Ranks: 1945
4.4
Recent Articles
1.
Gal P, Feldmajer G, Augusto M, Gani R, Hook E, Bullement A, et al.
Pharmacoeconomics
. 2025 Mar;
PMID: 40072777
No abstract available.
2.
Shah H, Jutlla G, Herrera-Restrepo O, Graham J, Grace M, Khan S, et al.
Pharmacoeconomics
. 2025 Mar;
PMID: 40072776
Background And Objective: Invasive meningococcal disease (IMD) is an uncommon but serious disease associated with a risk of death and severe long-term sequelae, impacting both patients and their caregivers. Productivity...
3.
Willis M, Nilsson A, Neslusan C
Pharmacoeconomics
. 2025 Mar;
PMID: 40057662
Patient-centered care emphasizes individual preferences, but insurer coverage decisions-based on population-level evidence-may restrict treatment options for patients who differ from the average. This highlights the importance of considering heterogeneity, which...
4.
Aluzaite K, Soares M, Hewitt C, Robotham J, Painter C, Woods B
Pharmacoeconomics
. 2025 Mar;
PMID: 40048093
Background And Objective: Economic evaluation of antimicrobial resistance (AMR) interventions is complicated by the multisectoral, inter-temporal and international aspects of the problem, further hindered by a lack of available data...
5.
Jakubczyk M, Roudijk B, Lipman S, Stalmeier P
Pharmacoeconomics
. 2025 Feb;
PMID: 40009331
Objective: The utilities elicited with the composite time trade-off (cTTO) method for health states worse-than-dead (WTD) often correlate poorly with other severity measures, indicating a poor sensitivity of cTTO. We...
6.
Zemplenyi A, Leonard J, Wright G, DiStefano M, Nair K, Anderson K, et al.
Pharmacoeconomics
. 2025 Feb;
PMID: 39982606
Objective: This study aims to evaluate the financial implications of implementing various payment models, including outcome-based agreements (OBAs), volume-based rebates, and guaranteed rebates, for the newly approved gene therapies, exagamglogene...
7.
Zeevat F, van der Pol S, Kieffer A, Postma M, Boersma C
Pharmacoeconomics
. 2025 Feb;
PMID: 39976899
Objectives: This study aimed to assess the cost effectiveness of nirsevimab, a recently authorized monoclonal antibody (mAb) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial...
8.
Norman R, Roudijk B, Jonker M, Stolk E, Knies S, Pwu R, et al.
Pharmacoeconomics
. 2025 Feb;
PMID: 39960567
Providing health-related quality of life (HRQoL) value sets to enable estimation of quality adjusted life years (QALYs) is important in facilitating economic evaluation and in supporting reliable decision-making about healthcare....
9.
Donoghue J, Youngs M, Reeve A, Vydyula K, Kunst N, Trikha R, et al.
Pharmacoeconomics
. 2025 Feb;
PMID: 39934600
In 2024, the National Institute for Health and Care Excellence (NICE) recommended two new health technologies for paroxysmal nocturnal haemoglobinuria. This review systematically compares the clinical and cost-effectiveness evidence considered...
10.
Kramer A, van Schaik L, van den Broek D, Meijer G, Gutierrez Ibarluzea I, Galnares Cordero L, et al.
Pharmacoeconomics
. 2025 Feb;
PMID: 39920559
Background: Cost-effectiveness analysis (CEA) of biomarkers is challenging due to the indirect impact on health outcomes and the lack of sufficient fit-for-purpose data. Hands-on guidance is lacking. Objective: We aimed...